{
  "trial_id": "NCT02304302",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Cytogenetically documented Trisomy 21 or Complete Unbalanced Translocation of Chromosome 21.",
      "label": "unknown"
    },
    {
      "criterion": "No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control.",
      "label": "met"
    },
    {
      "criterion": "Laboratory findings within normal limits or judged clinically insignificant at baseline",
      "label": "met"
    },
    {
      "criterion": "Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed",
      "label": "met"
    },
    {
      "criterion": "ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed",
      "label": "unknown"
    },
    {
      "criterion": "Participants and their authorized representatives will provide written informed consent",
      "label": "met"
    },
    {
      "criterion": "Participants who have received any experimental drug for Down syndrome must undergo a washout",
      "label": "unknown"
    },
    {
      "criterion": "All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication;",
      "label": "met"
    },
    {
      "criterion": "Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule",
      "label": "unknown"
    },
    {
      "criterion": "Be sufficiently proficient in English (USA) or Portuguese (Brazil) to reliably complete the study assessments",
      "label": "met"
    },
    {
      "criterion": "Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Participant weighing less than 40 kg",
      "label": "not_met"
    },
    {
      "criterion": "Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)",
      "label": "unknown"
    },
    {
      "criterion": "Current treatment with psychotropic drugs",
      "label": "not_met"
    },
    {
      "criterion": "Drug or alcohol abuse or dependence",
      "label": "not_met"
    },
    {
      "criterion": "Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.",
      "label": "unknown"
    },
    {
      "criterion": "Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)",
      "label": "not_met"
    },
    {
      "criterion": "Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)",
      "label": "unknown"
    },
    {
      "criterion": "Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information",
      "label": "not_met"
    }
  ],
  "notes": "The patient has a history of smoking and drinking, but no underlying disease. He is in good physical condition and has normal lab studies.",
  "_meta": {
    "topic_id": "48",
    "trial_id": "NCT02304302",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}